Purpose: To investigate glaucomatous damage in Boston keratoprosthesis type I (KPro) patients through structural analysis of the optic nerve head and digital planimetric quantification of Goldmann visual fields, a novel method of monitoring perimetric changes in KPro patients.
I mplantation of the Boston keratoprosthesis type I (KPro) is an established surgical treatment for a variety of corneal pathologies including recurrent corneal graft failure, infectious keratitis, chemical or thermal injury, and inflammatory keratitis. 1 Contemporary advancements in KPro device implantation and its postoperative management have increased rates of success and long-term device retention. 1 However, glaucomatous optic neuropathy associated with otherwise successful keratoprosthesis implantation may negatively impact visual outcomes. Glaucoma is the second most common complication of KPro implantation after retroprosthetic membrane formation and is a leading cause of permanent visual loss. 1 Patients requiring KPro implantation are at a particularly high risk of glaucoma for multiple reasons; the underlying ocular conditions necessitating KPro implantation may independently predispose to glaucoma (eg, aniridia, thermal injury, chemical injury, or multiple previous ocular surgeries) and the corneal pathology often precludes adequate glaucoma surveillance [eg, inability to adequately visualize the optic nerve head and inability to reliably obtain intraocular pressure (IOP) measurements]. 2 Furthermore, intraoperative factors (eg, mechanical distortion of the iridocorneal angle at the time of KPro implantation) and postoperative factors (eg, corticosteroid use, inflammation, or mechanical compromise of the iridocorneal angle) may also increase the risk of glaucoma. [2] [3] [4] [5] [6] [7] [8] Previous retrospective studies have revealed a high incidence of preexisting glaucoma in KPro patients (40.2%-89.3%); however, there is limited information regarding the development of de novo glaucoma and glaucoma progression after KPro implantation. 2, 5, 7, [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] In this study, the authors investigate glaucomatous optic neuropathy in KPro patients through structural analysis of the optic nerve head and digital planimetric quantification of Goldmann visual fields (GVF), a novel method of monitoring perimetric changes in KPro patients.
MATERIALS AND METHODS

Study Design
Electronic medical records were reviewed from consecutive patients who underwent KPro implantation performed by one of 2 surgeons (M.S.C. and J.D.C.) at the University of Illinois at Chicago from 2007 to 2015. The study protocol was approved by the Institutional Review Board of the University of Illinois at Chicago and adhered to the tenets of the Declaration of Helsinki.
Participants
Inclusion criteria limited patients to those with $1 year of postimplantation follow-up and $2 separate good quality optic nerve head photographs separated by $6 months. Additionally, most included patients also had at least 2 visual fields separated by $6 months using a Goldmann perimeter (Haag-Streit International, Koeniz, Switzerland).
Patient records were analyzed for patient age, sex, ethnicity, ocular history including presence or absence of glaucoma, baseline preoperative IOP, preoperative bestcorrected visual acuity (BCVA), preoperative number of glaucoma medications, and postoperative IOP, BCVA, and number of glaucoma medications within 1 month of the following time points-1, 3, 6, 12, 18, 24, 30, 36, 48, 60, and 72 months or at last follow-up. Serial optic disc photographs were analyzed and the vertical and horizontal cup-to-disc ratios (C/D) were graded by an independent ophthalmologist.
IOP Measurement
IOP was measured using scleral pneumotonometry (Mentor 30 Classic pneumatonometer; Mentor Inc, Norwell, MA) and digital palpation techniques. When IOP was measured by both scleral pneumotonometry (performed 2 mm posterior to the inferotemporal limbus) and digital palpation in a single clinical visit, preference was given to the IOP value obtained by scleral pneumotonometry unless there was documented concern regarding the reliability of the pneumotonometry measurement such as in excessive eyelid squeezing. The technique and utility of scleral pneumatonometry have been described previously. 22, 23 When IOP measurements by digital palpation were recorded as a range of values (eg, 10-15 mm Hg), the mean of the 2 values was used for statistical analysis. The proportion of patients with IOP .20 and .25 mm Hg on at least 2 separate clinical examinations was then determined.
Optic Nerve Head Imaging and Analysis
All optic nerve head photographs were performed by one of 2 experienced ophthalmic photographers. These photographs were subsequently examined by an independent glaucomatologist who was masked to all additional clinical data. Using stereopair images in Axis Image Management software (Sonomed Escalon, New Hyde Park, NY), the examiner delineated the optic disc and cup margins and recorded the vertical and horizontal cup-todisc ratios. Measurements were made using the software's cup-to-disc measurement tool when available or calculated from millimeter rule measurements made on magnified images. Poor-quality photographs in which the optic disc or cup margins could not reliably be delineated by the examiner were excluded.
Visual Field Testing and Analysis
GVFs were performed by experienced ophthalmic technicians. GVFs were scanned as digital images (Fig. 1 ) and analyzed in Adobe Photoshop CC 2015.1.1 (Adobe Systems Inc, San Jose, CA). Before analysis, the measurement scale for all visual fields was digitally calibrated such that the pixel distance from the visual field center to the 10 degrees radius was equivalent to 1.1 cm (Image: Analysis: Set measurement scale: Custom: Pixel length usually set at 94 pixels). This length was determined using the ruler tool to measure the pixel distance from the visual field center to the 10 degrees radius: logical length = 1.1: logical units = cm). Under high digital magnification (400%-700%), the magnetic lasso tool (Feather = 0 px, Width = 10 px, Contrast = 10%, Frequency = 85) was used to carefully delineate the outer edges of the technician-drawn lines for each isopter. If present, scotomas were also similarly delineated using the magnetic lasso tool, though with the "subtract from selection" option selected. The final total area was then calculated (Image: Analysis: Record measurements). Visual field deterioration was defined as a loss of more than 30% of the V4e isopter area. The V4e isopter was delineated on all patients and was therefore used for progression analysis; additionally, it was thought to be the most reproducible and least extinguishable isopter given its high luminescence and large target size.
Glaucoma Analysis
Patients were considered to demonstrate progression of preexisting glaucomatous optic neuropathy or development of de novo glaucoma after KPro implantation when an increase of $0.1 in the cup-to-disc ratio was observed or when there was a decrease in the V4e isopter area of greater than 30% in the GVF.
Statistical Analysis
All subjects underwent visual acuity testing using a Snellen chart. The BCVA was converted to the logarithm of the minimal angle of resolution (logMAR) for statistical analysis. When Snellen visual acuity could not be obtained, semiquantitative assessments of visual acuity were made (eg, count fingers, hand motions, light perception, or no light perception). For the purpose of statistical analysis, the following logMAR values were assigned: count fingers-logMAR 2.0, hand motions-logMAR 2.3, light perception-logMAR 2.6, no light perceptionlogMAR 3.0. 24, 25 
RESULTS
A total of 115 eyes of 109 patients underwent Boston keratoprosthesis type 1 implantation at the University of Illinois at Chicago from 2007 to 2015. A total of 22 eyes from 21 patients met inclusion criteria for final analysis. The demographic and clinical information of included patients are shown in Table 1 . Primary KPro implantation, defined as KPro implantation performed without a history of corneal transplantation, was performed in 7/22 eyes. Secondary KPro implantation, defined as KPro implantation performed in eyes with a history of corneal transplantation with subsequent immunologic rejection, occurred in 15/22 eyes. Post-KPro complications are listed in Table 2 , and outcomes are summarized in Table 3 .
Ninety-three eyes were excluded from analysis for various reasons, often multifactorial. Nineteen eyes (20.4% of excluded eyes) were lost to follow-up, 8 eyes (8.6%) had pale nerves with end-stage cupping before KPro implantation, and 4 eyes (4.3%) belonged to patients who became deceased during the study period. Two eyes (2.2%) received glaucoma care by outside providers. Many excluded eyes had media opacities precluding adequate fundus photography at the time of the study, including 34 eyes (37%) with primary and recurrent retroprosthetic membranes, 6 (6.5%) with previous vitrectomy surgery and silicone oil fill (including cases of egress into the anterior chamber), 3 (3.2%) with significant posterior capsule opacification, 2 (2.2%) with persistent epithelial disease and corneal haze, and 2 (2.2%) with chronic vitritis. Of eyes with clear media, 17 (18.3%) had nystagmus that prevented adequate fundus photography. Seventeen eyes (18.3%) also underwent KPro explantation (12 from corneal melts and 5 from endophthalmitis). Six eyes (6.5%) reached no light perception (NLP) vision during the study; these eyes had hand motion or light perception vision preoperatively, and reasons for vision loss included acanthamoeba infection with inconsistent follow-up, choroidal hemorrhage during KPro surgery, recurrent retinal detachments, endophthalmitis, and worsening of preexisting end-stage glaucoma. Finally, one eye was exenterated for basal cell carcinoma.
In total, 11 eyes in this series (50%) experienced elevated IOP above 20 mm Hg on 2 separate visits after KPro implantation. A vertical or horizontal C/D increase of $0.1 or $0.2 was seen in 5 (22.7%) and 1 (4.5%) eyes, respectively. Visual field deterioration (loss of .30% of the V4e isopter area) occurred in 2 of 16 eyes (12.5%) with GVFs at least 6 months apart (Fig. 1) . Development of post-KPro glaucoma, progression of preexisting or post-KPro glaucoma, and no glaucoma development as evidenced by the objective assessment of structural and clinical parameters were seen in 2/22 (9.1%), 7/22 (31.8%), and 6/22 (27.3%) eyes, respectively (Table 3) .
IOP-lowering surgical treatments in this series included Baerveldt-350 glaucoma drainage implants (Abbott Medical Optics, Inc, Santa Ana, CA), Ahmed-FP7 valve glaucoma drainage implants (New World Medical, Inc, Rancho Cucamonga, CA), Molteno drainage implants (Molteno Ophthalmic Ltd, Dunedin, New Zealand), trabeculectomy, and transscleral cyclophotocoagulation. All glaucoma drainage devices implanted concurrently or after KPro implantation were inserted through the pars plana, whereas glaucoma drainage devices implanted before KPro implantation were revised and repositioned through the pars plana at the time of KPro implantation. Of the 12 eyes that had IOP-lowering surgeries before or concurrent with KPro implantation, 5/12 showed evidence of progression and 2/12 underwent additional IOP-lowering surgery. Of the remaining 10 eyes that did not have previous or concurrent IOP-lowering surgeries, 4/10 ultimately underwent IOP-lowering surgeries.
DISCUSSION
With increased rates and longer durations of KPro retention, it has become evident that careful surveillance and treatment of glaucoma is essential to ensure the best possible visual outcomes in KPro patients. 1 The pathophysiology of glaucoma progression and development in KPro patients is complex and multifactorial. [2] [3] [4] [5] [6] [7] [8] Several conditions that lead patients to eventually require a keratoprosthesis are also independently associated with the development of glaucoma as evidenced by the rates of glaucoma in the following conditions: chemical burns (prevalence 22%-55%), aniridia (incidence 6%-75%, with prevalence as high as 91%), and penetrating keratoplasty (incidence 9%-31% in the early postoperative period, 18%-35% in the late postoperative period). 2 Furthermore, glaucoma is particularly challenging to diagnose, monitor, and treat in KPro patients. Preoperatively, glaucoma surveillance (eg, optic nerve evaluation, IOP monitoring, visual field testing, and optical coherence tomography testing) is often limited by corneal pathology and other comorbid conditions, thereby potentially permitting glaucomatous damage to proceed without being detected, monitored, or intervened upon. Likewise, postoperatively, glaucoma surveillance may be hindered by the keratoprosthesis itself and possibly further limited by secondary complications such as a retroprosthetic membrane. The most notably compromised glaucoma surveillance modality is IOP monitoring, but the quality of visual field testing, optical coherence tomography testing, and optic disc evaluation may also be affected. Intraoperatively, it is posited that there may be mechanical distortion of the iridocorneal angle at the time of KPro implantation, which may further contribute to glaucoma risk. 6 Numerous postoperative factors may also play an important role, including mechanical compromise and crowding of the iridocorneal angle by the KPro backplate, 2,4-6,8 obstruction of 4 and possibly reduced compliance with topical IOP-lowering medications (given the requirement to comply with multiple long-term topical medications). Importantly, a prospective study involving serial anterior segment optical coherence tomography has suggested high rates of progressive iridocorneal angle shallowing, peripheral anterior synechia formation, and secondary angle closure after KPro implantation (7/11 eyes, 63.6%). 6 The impact of glaucoma in KPro patients has been described previously. Several retrospective studies have revealed a high incidence of preoperatively diagnosed glaucoma in KPro patients, ranging from 33.3% to 89.3% (see Table 4 , Supplemental Digital Content 1, http://links.lww.com/ICO/A630).
Although not as well studied, high rates of progression of preoperatively diagnosed glaucoma (ranging from 18.5% to 72.2%) and postoperatively newly diagnosed glaucoma (0.0%-75.0%) have also been reported in other retrospective studies (see Table 4 , Supplemental Digital Content 1, http://links.lww.com/ICO/A630). As a result, this study endeavored to better investigate the incidence of preexisting glaucoma, de novo glaucoma, and progression of glaucoma in KPro recipients. Although many previous studies (see Table 4 , Supplemental Digital Content 1, http://links.lww.com/ICO/A630) have used elevated IOP or subjective assessments of glaucomatous damage by fundoscopy or review of visual fields by examining physicians, ours is among the few to use objective measurements of structural changes (analysis of cup-to-disc ratio measurements in disc photographs graded by an independent glaucomatologist) and functional changes (using a novel method for the quantification of GVFs in KPro patients) as the primary basis for determining whether and how glaucoma has affected KPro patients. The incidence of preexisting glaucoma in our patient population (14/22, 63.6%) is comparable to previous studies (mean 63.1%, 33.3%-89.3%, see Table 4 , Supplemental Digital Content 1, http://links.lww.com/ICO/A630). The incidence of progression of preexisting glaucoma in this study (5/14, 35 .7%) is also comparable to previous studies (mean 39.4%, see Table 4 , Supplemental Digital Content 1, http://links.lww.com/ICO/A630), although the incidence of post-KPro glaucoma is substantially lower in this study (2/22, 9 .1%) compared with previous studies (mean 45.6%). This represents among the lowest reported post-KPro glaucoma rates, second only to a previous case series from our institution (see Table 4 , Supplemental Digital Content 1, http://links.lww.com/ICO/A630). 13 We hypothesize that this may be at least somewhat attributable to a high rate of procedural or surgical IOP-lowering interventions in our study occurring concurrently with KPro implantation (45.5% vs. a mean of 21.7% among previous studies, see Table 4 , Supplemental Digital Content 1, http://links.lww.com/ICO/A630) or post-KPro implantation (27.3% vs. a mean of 12.9% among previous studies, see Table 4 , Supplemental Digital Content 1, http://links.lww.com/ICO/A630).
It is also important to note that in this case series, 19/22 (86.4%) eyes retained visual acuity $20/200 at last follow-up and no eyes had loss of visual acuity related to glaucoma progression. Additionally, the mean IOP pre-KPro and at last follow-up were identical (18.4 vs. 18.4 mm Hg), and the mean cup-to-disc ratios pre-KPro and at last follow-up were comparable (vertical, 0.48 vs. 0.50; horizontal, 0.52 vs. 0.52). A number of patients were excluded from the study for reasons such as severe media opacities precluding adequate fundus photography, thereby potentially biasing the final results toward better visual acuity and glaucoma management parameters. Nonetheless, we hypothesize that when a stringent methodology used for glaucoma assessment, as used in this study, is possible, it may allow for early detection of glaucomatous changes and minimization of glaucoma-associated visual acuity loss.
Given that glaucoma surveillance in KPro patients is particularly challenging, the investigation and implementation of novel surveillance methods in these patents are essential. The methods used in our study, including the use of digital planimetric analysis of GVFs, may serve well as the foundations for larger future studies investigating glaucoma in KPro patients. Options for functional visual field assessment include static automated perimetry or kinetic perimetry (GVF). Both methods may be significantly affected by refractive and ocular media changes as well as glare after keratoprosthesis implantation. 26 In this series, GVFs were selected for various reasons. GVFs were administered by experienced technicians, providing accuracy and repeatability. Furthermore, the ability to use standardized stimulus sizes and fixation targets with static automated perimetry is limited in KPro patients with central visual acuity ,20/200 or nystagmus. Additionally, assessment of the visual field beyond the central 24 degrees was preferred as little is known about patterns of field loss in KPro patients. The use of V4e may be less sensitive to detecting smaller glaucomatous changes compared with dimmer or smaller isopters. However, we limited our analysis to the V4e isopter for 2 major reasons: 1) a study by Sayegh et al used the Goldmann V4e isopter to study the optical functional properties of KPro devices, providing reasonable baseline parameters with which to compare progressive field loss 26 ; 2) all GVFs performed included the V4e isopter, allowing for consistent comparison between patients. Although the V4e isopter was chosen for analysis in this study, the technique of digital planimetric quantification can be readily applied to any isopter. We believe that the same method of planimetric analysis of GVFs may also be extended to other non-KPro patients with glaucoma as well, along with other nonglaucomatous conditions such as inherited retinal degenerations. 27 There are certain limitations to this study. It is a retrospective study, and the number of eyes included for final analysis is small relative to the overall number of KPro procedures performed at our institution. As mentioned earlier, there are several factors that likely account for this. First, the inclusion criteria requiring 2 separate, high-quality, gradable, disc photographs separated in time are more difficult to meet in KPro patients with potentially poor anterior segment transparency than the average patients with glaucoma. Second, the smaller sample size may at least partially be attributable to the changing views and priorities of examining physicians regarding glaucoma surveillance throughout the KPro era-in earlier years, baseline and follow-up disc photographs may not have been believed of as being a necessary part of routine care for KPro patients, whereas, nowadays at our institution, a shift has occurred to image nearly all patients with sufficiently transparent media. Despite the strict exclusion criteria, a long follow-up was achieved in this study (49.6 mo), allowing for the assessment and detection of short-term to long-term glaucomatous structural and functional changes in the included patients. Compared with other studies listed in Table 4 (Supplemental Digital Content 1, http://links.lww.com/ICO/A630), only 1 other study had a longer mean follow-up duration.
This study adds to the medical literature on glaucoma in KPro patients in 2 distinct ways. First, it bases an assessment of glaucoma development or progression on objective deterioration in structural and functional parameters. Second, it introduces the use of digital planimetric quantification of GVFs for the purpose of analyzing visual field changes in KPro patients. These methods may serve useful to aide in the important and challenging task of glaucoma surveillance.
Based on the findings of this study, we conclude that meticulous glaucoma surveillance with structural and functional testing combined with earlier IOP-lowering surgical intervention may result in decreased rates of glaucomatous vision loss in KPro patients. However, we acknowledge that successfully obtaining optic nerve imaging and visual fields in a number of patients with implanted KPro can be challenging, and further studies focusing on developing better ways to assess IOP and glaucoma detection and progression are needed.
